Assessment of Sexual Quality of Life Following Local Treatment (Radiotherapy With or Without Surg… (NCT07523152) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Assessment of Sexual Quality of Life Following Local Treatment (Radiotherapy With or Without Surgery) in Patients With HPV-positive Pelvic Cancer: a Descriptive Longitudinal Study
42 participantsStarted 2026-04-02
Plain-language summary
In patients with cancer associated with human papillomavirus (HPV), the physical effects of treatment, combined with the psychosexual impact linked to HPV status, can further impair the quality of sexual life.
However, few studies have examined the specific effect of HPV status (or knowledge of status) on the recovery/quality of sexuality following radiotherapy.
It is against this backdrop that we propose a prospective longitudinal study specifically dedicated to investigating the sexual quality of life of women with HPV-positive pelvic cancer.
This type of study will enable better quantification and description of sexual dysfunction occurring after treatment, and assessment of the impact of HPV carriage, with the future aim of guiding new prevention and management strategies.
Who can participate
Age range18 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Women aged 18 or over.
✓. Sexually active patients, i.e. those who have been sexually active in the year prior to their cancer diagnosis.
✓. Patients being treated at the Montpellier Cancer Institute (ICM).
✓. Patient with pelvic squamous cell carcinoma (cervix, vagina, vulva or anus) and human papillomavirus (HPV+) infection
✓. Patient aware of her HPV status and how it is transmitted.
✓. Indicated for external radiotherapy
✓. Patient who has not received any oncological treatment prior to inclusion.
✓. Patient who has given verbal consent.
Exclusion criteria
✕. Patients receiving radiotherapy treatment outside the Montpellier Cancer Institute (ICM).
✕. Patients who are unwilling or unable to complete the study questionnaires.
What they're measuring
1
To describe the quality of sexual life among patients treated (radiotherapy, with or without chemotherapy, and/or surgery) as part of the management of HPV-positive pelvic cancer.
Timeframe: at baseline, 3 months and 6 months after the end of all cancer treatment
Trial details
NCT IDNCT07523152
SponsorInstitut du Cancer de Montpellier - Val d'Aurelle